Compare BHM & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHM | PDSB |
|---|---|---|
| Founded | 2022 | 2005 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4M | 42.4M |
| IPO Year | 2022 | 2015 |
| Metric | BHM | PDSB |
|---|---|---|
| Price | $8.02 | $0.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $15.00 | $9.00 |
| AVG Volume (30 Days) | 2.7K | ★ 41.8M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $68,734,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.88 | N/A |
| 52 Week Low | $8.05 | $0.20 |
| 52 Week High | $13.30 | $1.55 |
| Indicator | BHM | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 81.39 |
| Support Level | $8.11 | $0.81 |
| Resistance Level | $8.97 | $1.11 |
| Average True Range (ATR) | 0.29 | 0.11 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 34.38 | 81.35 |
Bluerock Homes Trust Inc owns and operates a portfolio of institutional residential properties including single-family homes, build-to-rent communities, and other residential communities located in attractive markets with a focus on the knowledge-economy and high-quality of life growth markets of the Sunbelt and Western United States. The company's principal objective is to generate attractive risk-adjusted returns on investments where it believes it can drive growth in funds from operations and net asset value by acquiring residential units, developing residential communities, and through value-add renovations. The company has two reportable segments, consisting of Residential Communities, which derives maximum revenue; and Scattered Single-family homes.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.